ID   E2AK2_HUMAN             Reviewed;         551 AA.
AC   P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 2.
DT   12-OCT-2022, entry version 244.
DE   RecName: Full=Interferon-induced, double-stranded RNA-activated protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 2;
DE            Short=eIF-2A protein kinase 2;
DE   AltName: Full=Interferon-inducible RNA-dependent protein kinase;
DE   AltName: Full=P1/eIF-2A protein kinase;
DE   AltName: Full=Protein kinase RNA-activated;
DE            Short=PKR;
DE            Short=Protein kinase R {ECO:0000303|PubMed:11438532};
DE   AltName: Full=Tyrosine-protein kinase EIF2AK2;
DE            EC=2.7.10.2;
DE   AltName: Full=p68 kinase;
GN   Name=EIF2AK2; Synonyms=PKR, PRKR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 101-118 AND
RP   309-325, AND INDUCTION.
RX   PubMed=1695551; DOI=10.1016/0092-8674(90)90374-n;
RA   Meurs E., Chong K., Galabru J., Thomas N.S.B., Kerr I.M., Williams B.R.G.,
RA   Hovanessian A.G.;
RT   "Molecular cloning and characterization of the human double-stranded RNA-
RT   activated protein kinase induced by interferon.";
RL   Cell 62:379-390(1990).
RN   [2]
RP   SEQUENCE REVISION.
RA   Meurs E.;
RL   Submitted (AUG-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1373553; DOI=10.1016/0042-6822(92)90732-5;
RA   Thomis D.C., Doohan J.P., Samuel C.E.;
RT   "Mechanism of interferon action: cDNA structure, expression, and regulation
RT   of the interferon-induced, RNA-dependent P1/eIF-2 alpha protein kinase from
RT   human cells.";
RL   Virology 188:33-46(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=8921913; DOI=10.1016/0378-1119(96)00314-9;
RA   Kuhen K.L., Shen X., Samuel C.E.;
RT   "Mechanism of interferon action sequence of the human interferon-inducible
RT   RNA-dependent protein kinase (PKR) deduced from genomic clones.";
RL   Gene 178:191-193(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=8812437; DOI=10.1006/geno.1996.0446;
RA   Kuhen K.L., Shen X., Carlisle E.R., Richardson A.L., Weier H.-U.G.,
RA   Tanaka H., Samuel C.E.;
RT   "Structural organization of the human gene (PKR) encoding an interferon-
RT   inducible RNA-dependent protein kinase (PKR) and differences from its mouse
RT   homolog.";
RL   Genomics 36:197-201(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9726442; DOI=10.1089/jir.1998.18.609;
RA   Xu Z., Williams B.R.;
RT   "Genomic features of human PKR: alternative splicing and a polymorphic CGG
RT   repeat in the 5'-untranslated region.";
RL   J. Interferon Cytokine Res. 18:609-616(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Li H., Huang F., Shen C., Zhou G., Zheng G., Ke R., Lin L., Yang S.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-18; 27-40; 70-77; 414-426 AND 430-440, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Prostatic carcinoma;
RA   Bienvenut W.V., Gao M., Leug H.;
RL   Submitted (JUN-2009) to UniProtKB.
RN   [14]
RP   INTERACTION WITH DNAJC3.
RX   PubMed=8576172; DOI=10.1074/jbc.271.3.1702;
RA   Polyak S.J., Tang N., Wambach M., Barber G.N., Katze M.G.;
RT   "The P58 cellular inhibitor complexes with the interferon-induced, double-
RT   stranded RNA-dependent protein kinase, PKR, to regulate its
RT   autophosphorylation and activity.";
RL   J. Biol. Chem. 271:1702-1707(1996).
RN   [15]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=9079663; DOI=10.1074/jbc.272.13.8388;
RA   Brand S.R., Kobayashi R., Mathews M.B.;
RT   "The Tat protein of human immunodeficiency virus type 1 is a substrate and
RT   inhibitor of the interferon-induced, virally activated protein kinase,
RT   PKR.";
RL   J. Biol. Chem. 272:8388-8395(1997).
RN   [16]
RP   INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION).
RX   PubMed=9143277; DOI=10.1006/viro.1997.8493;
RA   Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A., Dever T.E.,
RA   Polyak S.J., Gretch D.R., Katze M.G.;
RT   "Evidence that hepatitis C virus resistance to interferon is mediated
RT   through repression of the PKR protein kinase by the nonstructural 5A
RT   protein.";
RL   Virology 230:217-227(1997).
RN   [17]
RP   INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION).
RX   PubMed=9710605; DOI=10.1128/mcb.18.9.5208;
RA   Gale M.J. Jr., Blakely C.M., Kwieciszewski B., Tan S.-L., Dossett M.,
RA   Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G.;
RT   "Control of PKR protein kinase by hepatitis C virus nonstructural 5A
RT   protein: molecular mechanisms of kinase regulation.";
RL   Mol. Cell. Biol. 18:5208-5218(1998).
RN   [18]
RP   INTERACTION WITH INFLUENZA A NS1 PROTEIN.
RX   PubMed=9781815; DOI=10.1089/jir.1998.18.757;
RA   Tan S.L., Katze M.G.;
RT   "Biochemical and genetic evidence for complex formation between the
RT   influenza A virus NS1 protein and the interferon-induced PKR protein
RT   kinase.";
RL   J. Interferon Cytokine Res. 18:757-766(1998).
RN   [19]
RP   INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION).
RX   PubMed=10390359; DOI=10.1126/science.285.5424.107;
RA   Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.;
RT   "Inhibition of the interferon-inducible protein kinase PKR by HCV E2
RT   protein.";
RL   Science 285:107-110(1999).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH IKBKB.
RX   PubMed=10848580; DOI=10.1128/mcb.20.13.4532-4542.2000;
RA   Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F.;
RT   "PKR stimulates NF-kappaB irrespective of its kinase function by
RT   interacting with the IkappaB kinase complex.";
RL   Mol. Cell. Biol. 20:4532-4542(2000).
RN   [21]
RP   INTERACTION WITH TARBP2.
RX   PubMed=11438532; DOI=10.1074/jbc.m103584200;
RA   Daher A., Longuet M., Dorin D., Bois F., Segeral E., Bannwarth S.,
RA   Battisti P.-L., Purcell D.F., Benarous R., Vaquero C., Meurs E.F.,
RA   Gatignol A.;
RT   "Two dimerization domains in the trans-activation response RNA-binding
RT   protein (TRBP) individually reverse the protein kinase R inhibition of HIV-
RT   1 long terminal repeat expression.";
RL   J. Biol. Chem. 276:33899-33905(2001).
RN   [22]
RP   PHOSPHORYLATION AT SER-83; THR-88; THR-89; THR-90; SER-242; THR-255 AND
RP   THR-258, MUTAGENESIS OF SER-83; THR-88; THR-89; THR-90; SER-242; THR-255;
RP   THR-258 AND LYS-296, AND INHIBITION BY HCV E2 ENVELOPE PROTEIN.
RX   PubMed=11152499; DOI=10.1128/jvi.75.3.1265-1273.2001;
RA   Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C.,
RA   Mathews M.B.;
RT   "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple
RT   competition with autophosphorylation sites in the RNA-binding domain.";
RL   J. Virol. 75:1265-1273(2001).
RN   [23]
RP   MUTAGENESIS OF LYS-60; ALA-67; THR-446 AND THR-451, AND PHOSPHORYLATION AT
RP   THR-446 AND THR-451.
RX   PubMed=11337501; DOI=10.1074/jbc.m102108200;
RA   Zhang F., Romano P.R., Nagamura-Inoue T., Tian B., Dever T.E.,
RA   Mathews M.B., Ozato K., Hinnebusch A.G.;
RT   "Binding of double-stranded RNA to protein kinase PKR is required for
RT   dimerization and promotes critical autophosphorylation events in the
RT   activation loop.";
RL   J. Biol. Chem. 276:24946-24958(2001).
RN   [24]
RP   INTERACTION WITH HHV-8 PROTEIN VIRF2 (MICROBIAL INFECTION).
RX   PubMed=11160738; DOI=10.1128/jvi.75.5.2345-2352.2001;
RA   Burysek L., Pitha P.M.;
RT   "Latently expressed human herpesvirus 8-encoded interferon regulatory
RT   factor 2 inhibits double-stranded RNA-activated protein kinase.";
RL   J. Virol. 75:2345-2352(2001).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH HHV-1 US11 (MICROBIAL INFECTION).
RX   PubMed=11836380; DOI=10.1128/jvi.76.5.2029-2035.2002;
RA   Cassady K.A., Gross M.;
RT   "The herpes simplex virus type 1 U(S)11 protein interacts with protein
RT   kinase R in infected cells and requires a 30-amino-acid sequence adjacent
RT   to a kinase substrate domain.";
RL   J. Virol. 76:2029-2035(2002).
RN   [26]
RP   INTERACTION WITH NPM1, AND ACTIVITY REGULATION.
RX   PubMed=12882984; DOI=10.1074/jbc.m301392200;
RA   Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W.,
RA   Faulkner G.R., Speckhart A., Bagby G.C.;
RT   "Nucleophosmin interacts with and inhibits the catalytic function of
RT   eukaryotic initiation factor 2 kinase PKR.";
RL   J. Biol. Chem. 278:41709-41717(2003).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH MAP2K6.
RX   PubMed=15229216; DOI=10.1074/jbc.m406554200;
RA   Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., Williams B.R.;
RT   "Protein kinase R (PKR) interacts with and activates mitogen-activated
RT   protein kinase kinase 6 (MKK6) in response to double-stranded RNA
RT   stimulation.";
RL   J. Biol. Chem. 279:37670-37676(2004).
RN   [28]
RP   IDENTIFICATION IN A COMPLEX WITH FANCA; FANCC; FANCG AND HSP70.
RX   PubMed=15299030; DOI=10.1074/jbc.m403884200;
RA   Zhang X., Li J., Sejas D.P., Rathbun K.R., Bagby G.C., Pang Q.;
RT   "The Fanconi anemia proteins functionally interact with the protein kinase
RT   regulated by RNA (PKR).";
RL   J. Biol. Chem. 279:43910-43919(2004).
RN   [29]
RP   FUNCTION, INTERACTION WITH TRAF2; TRAF5 AND TRAF6, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15121867; DOI=10.1128/mcb.24.10.4502-4512.2004;
RA   Gil J., Garcia M.A., Gomez-Puertas P., Guerra S., Rullas J., Nakano H.,
RA   Alcami J., Esteban M.;
RT   "TRAF family proteins link PKR with NF-kappa B activation.";
RL   Mol. Cell. Biol. 24:4502-4512(2004).
RN   [30]
RP   INHIBITION BY VACCINIA VIRUS PROTEIN E3.
RX   PubMed=15207627; DOI=10.1016/j.virol.2004.03.012;
RA   Langland J.O., Jacobs B.L.;
RT   "Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains
RT   of E3L.";
RL   Virology 324:419-429(2004).
RN   [31]
RP   REVIEW.
RX   PubMed=17158706; DOI=10.1128/mmbr.00027-06;
RA   Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C.,
RA   Esteban M.;
RT   "Impact of protein kinase PKR in cell biology: from antiviral to
RT   antiproliferative action.";
RL   Microbiol. Mol. Biol. Rev. 70:1032-1060(2006).
RN   [32]
RP   PHOSPHORYLATION AT TYR-101; TYR-162 AND TYR-293.
RX   PubMed=16373505; DOI=10.1073/pnas.0508207103;
RA   Su Q., Wang S., Baltzis D., Qu L.K., Wong A.H., Koromilas A.E.;
RT   "Tyrosine phosphorylation acts as a molecular switch to full-scale
RT   activation of the eIF2alpha RNA-dependent protein kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:63-68(2006).
RN   [33]
RP   INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION).
RX   PubMed=16951545;
RA   Liang Y., Kang C.B., Yoon H.S.;
RT   "Molecular and structural characterization of the domain 2 of hepatitis C
RT   virus non-structural protein 5A.";
RL   Mol. Cells 22:13-20(2006).
RN   [34]
RP   INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION).
RX   PubMed=17451199; DOI=10.3748/wjg.v13.i8.1195;
RA   Veillon P., Payan C., Le Guillou-Guillemette H., Gaudy C., Lunel F.;
RT   "Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b
RT   during interferon or combined interferon-ribavirin therapy.";
RL   World J. Gastroenterol. 13:1195-1203(2007).
RN   [35]
RP   INTERACTION WITH HCV MATURE CORE PROTEIN (MICROBIAL INFECTION).
RX   PubMed=17267064; DOI=10.1016/j.virusres.2006.12.010;
RA   Yan X.B., Battaglia S., Boucreux D., Chen Z., Brechot C., Pavio N.;
RT   "Mapping of the interacting domains of hepatitis C virus core protein and
RT   the double-stranded RNA-activated protein kinase PKR.";
RL   Virus Res. 125:79-87(2007).
RN   [36]
RP   INTERACTION WITH ADAR.
RX   PubMed=17079286; DOI=10.1128/jvi.01527-06;
RA   Nie Y., Hammond G.L., Yang J.H.;
RT   "Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus
RT   infection.";
RL   J. Virol. 81:917-923(2007).
RN   [37]
RP   REVIEW ON ACTIVITY REGULATION.
RX   PubMed=17196820; DOI=10.1016/j.tibs.2006.12.003;
RA   Cole J.L.;
RT   "Activation of PKR: an open and shut case?";
RL   Trends Biochem. Sci. 32:57-62(2007).
RN   [38]
RP   FUNCTION, INTERACTION WITH NCK1, AND ACTIVITY REGULATION.
RX   PubMed=18835251; DOI=10.1016/j.bbrc.2008.09.112;
RA   Cardin E., Larose L.;
RT   "Nck-1 interacts with PKR and modulates its activation by dsRNA.";
RL   Biochem. Biophys. Res. Commun. 377:231-235(2008).
RN   [39]
RP   INTERACTION WITH DUS2L, AND ACTIVITY REGULATION.
RX   PubMed=18096616; DOI=10.1093/nar/gkm1129;
RA   Mittelstadt M., Frump A., Khuu T., Fowlkes V., Handy I., Patel C.V.,
RA   Patel R.C.;
RT   "Interaction of human tRNA-dihydrouridine synthase-2 with interferon-
RT   induced protein kinase PKR.";
RL   Nucleic Acids Res. 36:998-1008(2008).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83 AND SER-456, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [41]
RP   FUNCTION.
RX   PubMed=19507191; DOI=10.1002/jcp.21848;
RA   Blalock W.L., Grimaldi C., Fala F., Follo M., Horn S., Basecke J.,
RA   Martinelli G., Cocco L., Martelli A.M.;
RT   "PKR activity is required for acute leukemic cell maintenance and growth: a
RT   role for PKR-mediated phosphatase activity to regulate GSK-3
RT   phosphorylation.";
RL   J. Cell. Physiol. 221:232-241(2009).
RN   [42]
RP   FUNCTION, AND INTERACTION WITH DHX9.
RX   PubMed=19229320; DOI=10.1371/journal.ppat.1000311;
RA   Sadler A.J., Latchoumanin O., Hawkes D., Mak J., Williams B.R.;
RT   "An antiviral response directed by PKR phosphorylation of the RNA helicase
RT   A.";
RL   PLoS Pathog. 5:E1000311-E1000311(2009).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [44]
RP   FUNCTION IN HCV RESTRICTION.
RX   PubMed=19189853; DOI=10.1016/j.virusres.2009.01.007;
RA   Kang J.I., Kwon S.N., Park S.H., Kim Y.K., Choi S.Y., Kim J.P., Ahn B.Y.;
RT   "PKR protein kinase is activated by hepatitis C virus and inhibits viral
RT   replication through translational control.";
RL   Virus Res. 142:51-56(2009).
RN   [45]
RP   FUNCTION.
RX   PubMed=20171114; DOI=10.1016/j.cyto.2010.01.008;
RA   Lin S.S., Lee D.C., Law A.H., Fang J.W., Chua D.T., Lau A.S.;
RT   "A role for protein kinase PKR in the mediation of Epstein-Barr virus
RT   latent membrane protein-1-induced IL-6 and IL-10 expression.";
RL   Cytokine 50:210-219(2010).
RN   [46]
RP   FUNCTION AS CDK1 KINASE UPON DNA DAMAGE, AND FUNCTION AS TYROSINE-PROTEIN
RP   KINASE.
RX   PubMed=20395957; DOI=10.1038/embor.2010.45;
RA   Yoon C.-H., Miah M.A., Kim K.P., Bae Y.-S.;
RT   "New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers
RT   Cdc2 polyubiquitination and G2 arrest under genotoxic stresses.";
RL   EMBO Rep. 11:393-399(2010).
RN   [47]
RP   FUNCTION.
RX   PubMed=21123651; DOI=10.1101/gad.1965010;
RA   Harashima A., Guettouche T., Barber G.N.;
RT   "Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase
RT   PKR constitutes a novel mechanism of translational regulation and cellular
RT   defense.";
RL   Genes Dev. 24:2640-2653(2010).
RN   [48]
RP   INTERACTION WITH HRSV NUCLEOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=20519500; DOI=10.1074/jbc.m109.077321;
RA   Groskreutz D.J., Babor E.C., Monick M.M., Varga S.M., Hunninghake G.W.;
RT   "Respiratory syncytial virus limits alpha subunit of eukaryotic translation
RT   initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and
RT   viral replication.";
RL   J. Biol. Chem. 285:24023-24031(2010).
RN   [49]
RP   FUNCTION IN HCV RESTRICTION.
RX   PubMed=19840259; DOI=10.1111/j.1478-3231.2009.02144.x;
RA   Chang J.H., Kato N., Muroyama R., Taniguchi H., Guleng B., Dharel N.,
RA   Shao R.X., Tateishi K., Jazag A., Kawabe T., Omata M.;
RT   "Double-stranded RNA-activated protein kinase inhibits hepatitis C virus
RT   replication but may be not essential in interferon treatment.";
RL   Liver Int. 30:311-318(2010).
RN   [50]
RP   FUNCTION, AND PHOSPHORYLATION AT THR-451.
RX   PubMed=20685959; DOI=10.1091/mbc.e10-06-0481;
RA   Yang X., Nath A., Opperman M.J., Chan C.;
RT   "The double-stranded RNA-dependent protein kinase differentially regulates
RT   insulin receptor substrates 1 and 2 in HepG2 cells.";
RL   Mol. Biol. Cell 21:3449-3458(2010).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [52]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [53]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=21029237; DOI=10.1111/j.1750-3639.2010.00437.x;
RA   Bose A., Mouton-Liger F., Paquet C., Mazot P., Vigny M., Gray F., Hugon J.;
RT   "Modulation of tau phosphorylation by the kinase PKR: implications in
RT   Alzheimer's disease.";
RL   Brain Pathol. 21:189-200(2011).
RN   [54]
RP   REVIEW.
RX   PubMed=21924887; DOI=10.1016/j.coi.2011.08.009;
RA   Pfaller C.K., Li Z., George C.X., Samuel C.E.;
RT   "Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old
RT   players as modulators of the interferon response.";
RL   Curr. Opin. Immunol. 23:573-582(2011).
RN   [55]
RP   REVIEW.
RX   PubMed=21166592; DOI=10.1089/jir.2010.0099;
RA   Pindel A., Sadler A.;
RT   "The role of protein kinase R in the interferon response.";
RL   J. Interferon Cytokine Res. 31:59-70(2011).
RN   [56]
RP   FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   PHOSPHORYLATION.
RX   PubMed=21072047; DOI=10.1038/leu.2010.264;
RA   Blalock W.L., Bavelloni A., Piazzi M., Tagliavini F., Faenza I.,
RA   Martelli A.M., Follo M.Y., Cocco L.;
RT   "Multiple forms of PKR present in the nuclei of acute leukemia cells
RT   represent an active kinase that is responsive to stress.";
RL   Leukemia 25:236-245(2011).
RN   [57]
RP   FUNCTION IN HBV RESTRICTION.
RX   PubMed=21710204; DOI=10.1007/s10059-011-1059-6;
RA   Park I.H., Baek K.W., Cho E.Y., Ahn B.Y.;
RT   "PKR-dependent mechanisms of interferon-? for inhibiting hepatitis B virus
RT   replication.";
RL   Mol. Cells 32:167-172(2011).
RN   [58]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22214662; DOI=10.4161/cc.11.2.18999;
RA   Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.;
RT   "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and
RT   activation, leading to G(1) arrest.";
RL   Cell Cycle 11:407-417(2012).
RN   [59]
RP   REVIEW.
RX   PubMed=22633454; DOI=10.1016/j.immuni.2012.05.010;
RA   Lacy-Hulbert A., Stuart L.M.;
RT   "Penetration resistance: PKR's other talent.";
RL   Immunity 36:695-696(2012).
RN   [60]
RP   FUNCTION.
RX   PubMed=22948139; DOI=10.1074/jbc.m112.390039;
RA   McAllister C.S., Taghavi N., Samuel C.E.;
RT   "Protein kinase PKR amplification of interferon beta induction occurs
RT   through initiation factor eIF-2alpha-mediated translational control.";
RL   J. Biol. Chem. 287:36384-36392(2012).
RN   [61]
RP   FUNCTION, AND INTERACTION WITH STAT3.
RX   PubMed=23084476; DOI=10.1016/j.molcel.2012.09.013;
RA   Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H.,
RA   Souquere S., Marino G., Lachkar S., Senovilla L., Galluzzi L., Kepp O.,
RA   Pierron G., Maiuri M.C., Hikita H., Kroemer R., Kroemer G.;
RT   "Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity.";
RL   Mol. Cell 48:667-680(2012).
RN   [62]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [63]
RP   FUNCTION, INTERACTION WITH NLRP1; NLRP3; NLRC4 AND AIM2, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=22801494; DOI=10.1038/nature11290;
RA   Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P.,
RA   Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y.,
RA   Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U.,
RA   Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.;
RT   "Novel role of PKR in inflammasome activation and HMGB1 release.";
RL   Nature 488:670-674(2012).
RN   [64]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [65]
RP   REVIEW.
RX   PubMed=23092889; DOI=10.1126/scisignal.2003511;
RA   Kang R., Tang D.;
RT   "PKR-dependent inflammatory signals.";
RL   Sci. Signal. 5:PE47-PE47(2012).
RN   [66]
RP   FUNCTION.
RX   PubMed=22381929; DOI=10.1016/j.virol.2012.01.029;
RA   Taghavi N., Samuel C.E.;
RT   "Protein kinase PKR catalytic activity is required for the PKR-dependent
RT   activation of mitogen-activated protein kinases and amplification of
RT   interferon beta induction following virus infection.";
RL   Virology 427:208-216(2012).
RN   [67]
RP   REVIEW.
RX   PubMed=23202496; DOI=10.3390/v4112598;
RA   Dabo S., Meurs E.F.;
RT   "dsRNA-dependent protein kinase PKR and its role in stress, signaling and
RT   HCV infection.";
RL   Viruses 4:2598-2635(2012).
RN   [68]
RP   TISSUE SPECIFICITY.
RX   PubMed=23403623; DOI=10.1182/blood-2012-09-456400;
RA   Liu X., Bennett R.L., Cheng X., Byrne M., Reinhard M.K., May W.S. Jr.;
RT   "PKR regulates proliferation, differentiation and survival of murine
RT   hematopoietic stem/progenitor cells.";
RL   Blood 121:3364-3374(2013).
RN   [69]
RP   REVIEW.
RX   PubMed=23354059; DOI=10.1007/s00018-012-1252-6;
RA   Donnelly N., Gorman A.M., Gupta S., Samali A.;
RT   "The eIF2alpha kinases: their structures and functions.";
RL   Cell. Mol. Life Sci. 70:3493-3511(2013).
RN   [70]
RP   FUNCTION, ISGYLATION AT LYS-69 AND LYS-159, AND ACTIVITY REGULATION.
RX   PubMed=23229543; DOI=10.1074/jbc.m112.401851;
RA   Okumura F., Okumura A.J., Uematsu K., Hatakeyama S., Zhang D.E., Kamura T.;
RT   "Activation of double-stranded RNA-activated protein kinase (PKR) by
RT   interferon-stimulated gene 15 (ISG15) modification down-regulates protein
RT   translation.";
RL   J. Biol. Chem. 288:2839-2847(2013).
RN   [71]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [72]
RP   INTERACTION WITH TOSCANA VIRUS PROTEIN NSS (MICROBIAL INFECTION), AND
RP   ACTIVITY REGULATION.
RX   PubMed=23325696; DOI=10.1128/jvi.02506-12;
RA   Kalveram B., Ikegami T.;
RT   "Toscana virus NSs protein promoftes degradation of double-stranded RNA-
RT   dependent protein kinase.";
RL   J. Virol. 87:3710-3718(2013).
RN   [73]
RP   FUNCTION IN MV RESTRICTION.
RX   PubMed=23115276; DOI=10.1128/jvi.02270-12;
RA   Okonski K.M., Samuel C.E.;
RT   "Stress granule formation induced by measles virus is protein kinase PKR
RT   dependent and impaired by RNA adenosine deaminase ADAR1.";
RL   J. Virol. 87:756-766(2013).
RN   [74]
RP   FUNCTION.
RX   PubMed=23372823; DOI=10.1371/journal.pone.0055108;
RA   Li Y., Xie J., Wu S., Xia J., Zhang P., Liu C., Zhang P., Huang X.;
RT   "Protein kinase regulated by dsRNA downregulates the interferon production
RT   in dengue virus- and dsrna-stimulated human lung epithelial cells.";
RL   PLoS ONE 8:E55108-E55108(2013).
RN   [75]
RP   FUNCTION IN HCV RESTRICTION.
RX   PubMed=23399035; DOI=10.1016/j.virol.2013.01.015;
RA   Zhang L., Alter H.J., Wang H., Jia S., Wang E., Marincola F.M., Shih J.W.,
RA   Wang R.Y.;
RT   "The modulation of hepatitis C virus 1a replication by PKR is dependent on
RT   NF-kB mediated interferon beta response in Huh7.5.1 cells.";
RL   Virology 438:28-36(2013).
RN   [76]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [77]
RP   INTERACTION WITH VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION).
RX   PubMed=25740987; DOI=10.1128/jvi.03288-14;
RA   Dueck K.J., Hu Y.S., Chen P., Deschambault Y., Lee J., Varga J., Cao J.;
RT   "Mutational analysis of vaccinia virus E3 protein: the biological functions
RT   do not correlate with its biochemical capacity to bind double-stranded
RT   RNA.";
RL   J. Virol. 89:5382-5394(2015).
RN   [78]
RP   STRUCTURE BY NMR OF 1-175.
RX   PubMed=9736623; DOI=10.1093/emboj/17.18.5458;
RA   Nanduri S., Carpick B.W., Yang Y., Williams B.R.G., Qin J.;
RT   "Structure of the double-stranded RNA-binding domain of the protein kinase
RT   PKR reveals the molecular basis of its dsRNA-mediated activation.";
RL   EMBO J. 17:5458-5465(1998).
RN   [79]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 258-550 IN COMPLEX WITH EIF2ALPHA,
RP   AND PHOSPHORYLATION AT THR-446.
RX   PubMed=16179258; DOI=10.1016/j.cell.2005.06.044;
RA   Dar A.C., Dever T.E., Sicheri F.;
RT   "Higher-order substrate recognition of eIF2alpha by the RNA-dependent
RT   protein kinase PKR.";
RL   Cell 122:887-900(2005).
RN   [80]
RP   INVOLVEMENT IN LEUDEN, FUNCTION, VARIANTS LEUDEN LEU-11; SER-32; PHE-97;
RP   SER-109; VAL-109; PHE-133; SER-325 AND CYS-461, CHARACTERIZATION OF
RP   VARIANTS LEUDEN LEU-11; PHE-133 AND CYS-461, AND VARIANT GLN-114.
RX   PubMed=32197074; DOI=10.1016/j.ajhg.2020.02.016;
RG   Undiagnosed Diseases Network;
RA   Mao D., Reuter C.M., Ruzhnikov M.R.Z., Beck A.E., Farrow E.G., Emrick L.T.,
RA   Rosenfeld J.A., Mackenzie K.M., Robak L., Wheeler M.T., Burrage L.C.,
RA   Jain M., Liu P., Calame D., Kuery S., Sillesen M., Schmitz-Abe K.,
RA   Tonduti D., Spaccini L., Iascone M., Genetti C.A., Koenig M.K., Graf M.,
RA   Tran A., Alejandro M., Lee B.H., Thiffault I., Agrawal P.B.,
RA   Bernstein J.A., Bellen H.J., Chao H.T.;
RT   "De novo EIF2AK1 and EIF2AK2 variants are associated with developmental
RT   delay, leukoencephalopathy, and neurologic decompensation.";
RL   Am. J. Hum. Genet. 106:570-583(2020).
RN   [81]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [82]
RP   VARIANTS DYT33 THR-32; ARG-130 AND ALA-138, CHARACTERIZATION OF VARIANTS
RP   DYT33 THR-32 AND ARG-130, AND INVOLVEMENT IN DYT33.
RX   PubMed=33236446; DOI=10.1002/ana.25973;
RA   Kuipers D.J.S., Mandemakers W., Lu C.S., Olgiati S., Breedveld G.J.,
RA   Fevga C., Tadic V., Carecchio M., Osterman B., Sagi-Dain L., Wu-Chou Y.H.,
RA   Chen C.C., Chang H.C., Wu S.L., Yeh T.H., Weng Y.H., Elia A.E.,
RA   Panteghini C., Marotta N., Pauly M.G., Kuehn A.A., Volkmann J., Lace B.,
RA   Meijer I.A., Kandaswamy K., Quadri M., Garavaglia B., Lohmann K., Bauer P.,
RA   Mencacci N.E., Lubbe S.J., Klein C., Bertoli-Avella A.M., Bonifati V.;
RT   "EIF2AK2 Missense Variants Associated with Early Onset Generalized
RT   Dystonia.";
RL   Ann. Neurol. 89:485-497(2021).
RN   [83]
RP   VARIANT DYT33 ARG-130, AND INVOLVEMENT IN DYT33.
RX   PubMed=33866603; DOI=10.1002/ana.26081;
RA   Musacchio T., Zech M., Reich M.M., Winkelmann J., Volkmann J.;
RT   "A Recurrent EIF2AK2 Missense Variant Causes Autosomal-Dominant Isolated
RT   Dystonia.";
RL   Ann. Neurol. 89:1257-1258(2021).
RN   [84]
RP   VARIANT DYT33 ARG-130.
RX   PubMed=35146068; DOI=10.1002/mdc3.13371;
RA   Magrinelli F., Moualek D., Tazir M., Pacha L.A., Verghese A., Bhatia K.P.,
RA   Maroofian R., Houlden H.;
RT   "Heterozygous EIF2AK2 Variant Causes Adolescence-Onset Generalized Dystonia
RT   Partially Responsive to DBS.";
RL   Mov. Disord. Clin. Pract. 9:268-271(2022).
CC   -!- FUNCTION: IFN-induced dsRNA-dependent serine/threonine-protein kinase
CC       that phosphorylates the alpha subunit of eukaryotic translation
CC       initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the
CC       innate immune response to viral infection (PubMed:18835251,
CC       PubMed:19507191, PubMed:19189853, PubMed:21123651, PubMed:21072047,
CC       PubMed:22948139, PubMed:23229543, PubMed:22381929). Inhibits viral
CC       replication via the integrated stress response (ISR): EIF2S1/eIF-2-
CC       alpha phosphorylation in response to viral infection converts
CC       EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting
CC       to a shutdown of cellular and viral protein synthesis, while
CC       concomitantly initiating the preferential translation of ISR-specific
CC       mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853,
CC       PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its
CC       antiviral activity on a wide range of DNA and RNA viruses including
CC       hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV)
CC       and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853,
CC       PubMed:20171114, PubMed:19840259, PubMed:21710204, PubMed:23115276,
CC       PubMed:23399035). Also involved in the regulation of signal
CC       transduction, apoptosis, cell proliferation and differentiation:
CC       phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9,
CC       ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380,
CC       PubMed:22214662, PubMed:19229320). In addition to serine/threonine-
CC       protein kinase activity, also has tyrosine-protein kinase activity and
CC       phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its
CC       ubiquitination and proteosomal degradation (PubMed:20395957). Either as
CC       an adapter protein and/or via its kinase activity, can regulate various
CC       signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling
CC       pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3)
CC       involved in the expression of genes encoding pro-inflammatory cytokines
CC       and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates
CC       the NF-kappa-B pathway via interaction with IKBKB and TRAF family of
CC       proteins and activates the p38 MAP kinase pathway via interaction with
CC       MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as
CC       both a positive and negative regulator of the insulin signaling pathway
CC       (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the
CC       inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at
CC       'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A
CC       which activates FOXO1, which in turn up-regulates the expression of
CC       insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate
CC       NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2
CC       and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the
CC       regulation of the cytoskeleton by binding to gelsolin (GSN),
CC       sequestering the protein in an inactive conformation away from actin
CC       (By similarity). {ECO:0000250|UniProtKB:Q03963,
CC       ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,
CC       ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,
CC       ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,
CC       ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,
CC       ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,
CC       ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,
CC       ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,
CC       ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,
CC       ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,
CC       ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,
CC       ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,
CC       ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035,
CC       ECO:0000269|PubMed:32197074}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10027};
CC   -!- ACTIVITY REGULATION: Initially produced in an inactive form and is
CC       activated by binding to viral dsRNA, which causes dimerization and
CC       autophosphorylation in the activation loop and stimulation of function.
CC       ISGylation can activate it in the absence of viral infection. Can also
CC       be activated by heparin, pro-inflammatory stimuli, growth factors,
CC       cytokines, oxidative stress and the cellular protein PRKRA. Activity is
CC       markedly stimulated by manganese ions. Activation is blocked by the
CC       viral components HIV-1 Tat protein and large amounts of HIV-1 trans-
CC       activation response (TAR) RNA element as well as by the cellular
CC       proteins TARBP2, DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana
CC       virus (TOS) and Rift valley fever virus (RVFV) NSS which promote its
CC       proteasomal degradation. Inhibited by vaccinia virus protein E3,
CC       probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,
CC       ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,
CC       ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.
CC   -!- SUBUNIT: Homodimer. Interacts with STRBP (By similarity). Interacts
CC       with DNAJC3. Forms a complex with FANCA, FANCC, FANCG and HSP70.
CC       Interacts with ADAR/ADAR1. Interacts with IRS1 (By similarity). The
CC       inactive form interacts with NCK1 and GSN. Interacts (via the kinase
CC       catalytic domain) with STAT3 (via SH2 domain), TRAF2 (C-terminus),
CC       TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6,
CC       IKBKB/IKKB, NPM1, TARBP2, NLRP1, NLRP3, NLRC4 and AIM2. Interacts (via
CC       DRBM 1 domain) with DUS2L (via DRBM domain). Interacts with DHX9 (via
CC       N-terminus) and this interaction is dependent upon activation of the
CC       kinase. {ECO:0000250|UniProtKB:Q03963, ECO:0000269|PubMed:10390359,
CC       ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11438532,
CC       ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,
CC       ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,
CC       ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,
CC       ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,
CC       ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,
CC       ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:25740987,
CC       ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,
CC       ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human herpes simplex
CC       virus 1 (HHV-1) protein US11 in an RNA-dependent manner.
CC       {ECO:0000269|PubMed:11836380}.
CC   -!- SUBUNIT: (Microbial infection) The inactive form interacts with Toscana
CC       virus (TOS) NSS. {ECO:0000269|PubMed:23325696}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein v-
CC       IRF2; this interaction inhibits EIF2AK2 activation.
CC       {ECO:0000269|PubMed:11160738}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with vaccinia protein E3.
CC       {ECO:0000269|PubMed:25740987}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with
CC       Hepatitis C virus (HCV) mature core protein (via N-terminus); this
CC       interaction induces the autophosphorylation of EIF2AK2.
CC       {ECO:0000269|PubMed:17267064}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV)
CC       non-structural protein 5A (NS5A); this interaction leads to disruption
CC       of EIF2AK2 dimerization by NS5A. {ECO:0000269|PubMed:16951545,
CC       ECO:0000269|PubMed:17451199, ECO:0000269|PubMed:9143277,
CC       ECO:0000269|PubMed:9710605}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV)
CC       envelope glycoprotein E2; this interaction inhibits EIF2AK2 and blocks
CC       its inhibitory effect on protein synthesis and cell growth.
CC       {ECO:0000269|PubMed:9143277}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human respiratory
CC       syncytial virus (HRSV) nucleoprotein; this interaction inhibits EIF2AK2
CC       phosphorylation of EIF2S1 and blocks EIF2AK2-mediated translation
CC       shutoff. {ECO:0000269|PubMed:20519500}.
CC   -!- INTERACTION:
CC       P19525; P78563-4: ADARB1; NbExp=3; IntAct=EBI-640775, EBI-12002366;
CC       P19525; P06493: CDK1; NbExp=4; IntAct=EBI-640775, EBI-444308;
CC       P19525; Q7L2E3: DHX30; NbExp=4; IntAct=EBI-640775, EBI-1211456;
CC       P19525; Q96C10: DHX58; NbExp=2; IntAct=EBI-640775, EBI-744193;
CC       P19525; Q08211: DHX9; NbExp=2; IntAct=EBI-640775, EBI-352022;
CC       P19525; Q9UPY3: DICER1; NbExp=2; IntAct=EBI-640775, EBI-395506;
CC       P19525; Q6P2E9: EDC4; NbExp=2; IntAct=EBI-640775, EBI-1006038;
CC       P19525; P19525: EIF2AK2; NbExp=2; IntAct=EBI-640775, EBI-640775;
CC       P19525; P05198: EIF2S1; NbExp=5; IntAct=EBI-640775, EBI-1056162;
CC       P19525; P56537: EIF6; NbExp=2; IntAct=EBI-640775, EBI-372243;
CC       P19525; Q8IY81: FTSJ3; NbExp=3; IntAct=EBI-640775, EBI-744088;
CC       P19525; Q9HCE1: MOV10; NbExp=3; IntAct=EBI-640775, EBI-1055820;
CC       P19525; Q96P20: NLRP3; NbExp=6; IntAct=EBI-640775, EBI-6253230;
CC       P19525; P06748: NPM1; NbExp=3; IntAct=EBI-640775, EBI-78579;
CC       P19525; O75569: PRKRA; NbExp=6; IntAct=EBI-640775, EBI-713955;
CC       P19525; O75569-1: PRKRA; NbExp=3; IntAct=EBI-640775, EBI-15588172;
CC       P19525; Q9NUL3: STAU2; NbExp=3; IntAct=EBI-640775, EBI-722938;
CC       P19525; Q15633: TARBP2; NbExp=2; IntAct=EBI-640775, EBI-978581;
CC       P19525; Q9H0E2: TOLLIP; NbExp=2; IntAct=EBI-640775, EBI-74615;
CC       P19525; Q9UL40: ZNF346; NbExp=3; IntAct=EBI-640775, EBI-2462313;
CC       P19525; Q27968: DNAJC3; Xeno; NbExp=5; IntAct=EBI-640775, EBI-640793;
CC       P19525; P20639: K3L; Xeno; NbExp=3; IntAct=EBI-640775, EBI-8674942;
CC       P19525; P0DTC9: N; Xeno; NbExp=8; IntAct=EBI-640775, EBI-25475856;
CC       P19525; P04487: US11; Xeno; NbExp=3; IntAct=EBI-640775, EBI-6150681;
CC       P19525; Q2HR71: vIRF-2; Xeno; NbExp=2; IntAct=EBI-640775, EBI-8876177;
CC       P19525; PRO_0000278746 [O92972]; Xeno; NbExp=2; IntAct=EBI-640775, EBI-6918883;
CC       P19525; PRO_0000037570 [P27958]; Xeno; NbExp=4; IntAct=EBI-640775, EBI-6904269;
CC       P19525; PRO_0000037576 [P27958]; Xeno; NbExp=5; IntAct=EBI-640775, EBI-8753518;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15121867,
CC       ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:22214662}. Nucleus
CC       {ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}. Cytoplasm,
CC       perinuclear region {ECO:0000269|PubMed:15121867}. Note=Nuclear
CC       localization is elevated in acute leukemia, myelodysplastic syndrome
CC       (MDS), melanoma, breast, colon, prostate and lung cancer patient
CC       samples or cell lines as well as neurocytes from advanced Creutzfeldt-
CC       Jakob disease patients. {ECO:0000269|PubMed:21072047}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P19525-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19525-2; Sequence=VSP_046177;
CC   -!- TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bone marrow
CC       compared to non-hematopoietic tissues such as small intestine, liver,
CC       or kidney tissues. Colocalizes with GSK3B and TAU in the Alzheimer
CC       disease (AD) brain. Elevated levels seen in breast and colon
CC       carcinomas, and which correlates with tumor progression and
CC       invasiveness or risk of progression. {ECO:0000269|PubMed:21029237,
CC       ECO:0000269|PubMed:23403623}.
CC   -!- INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.
CC   -!- PTM: Autophosphorylated on several Ser, Thr and Tyr residues.
CC       Autophosphorylation of Thr-451 is dependent on Thr-446 and is
CC       stimulated by dsRNA binding and dimerization. Autophosphorylation
CC       apparently leads to the activation of the kinase. Tyrosine
CC       autophosphorylation is essential for efficient dsRNA-binding,
CC       dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,
CC       ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,
CC       ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,
CC       ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.
CC   -!- DISEASE: Leukoencephalopathy, developmental delay, and episodic
CC       neurologic regression syndrome (LEUDEN) [MIM:618877]: An autosomal
CC       dominant disorder characterized by global developmental delay apparent
CC       in early childhood, cognitive impairment, ataxia, poor or absent speech
CC       with dysarthria, hypotonia, hypertonia, extrapyramidal signs, tremor,
CC       and abnormal involuntary movements. Affected individuals also exhibit
CC       neurological regression in the setting of febrile illness or infection.
CC       Many patients have seizures. Brain imaging shows diffuse white matter
CC       abnormalities with poor myelination. {ECO:0000269|PubMed:32197074}.
CC       Note=The disease may be caused by variants affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Dystonia 33 (DYT33) [MIM:619687]: A form of dystonia, a
CC       disorder defined by the presence of sustained involuntary muscle
CC       contraction, often leading to abnormal postures. DYT33 is a slowly
CC       progressive form characterized by onset of focal or generalized
CC       dystonia in the first decades of life. Disease manifestations are
CC       variable. Some patients show ambulation difficulties, dysarthria, or
CC       dysphagia. Some affected individuals may manifest motor delay, lower
CC       limb spasticity, and mild developmental delay with intellectual
CC       disability. DYT33 penetrance is incomplete. Inheritance can be
CC       autosomal dominant or recessive. {ECO:0000269|PubMed:33236446,
CC       ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/prkr/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M35663; AAA36409.1; -; mRNA.
DR   EMBL; M85294; AAA18253.1; -; mRNA.
DR   EMBL; U50648; AAC50768.1; -; Genomic_DNA.
DR   EMBL; U50634; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50635; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50636; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50637; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50638; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50639; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50640; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50641; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50642; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50643; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50644; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50645; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50646; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50647; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; AF167472; AAF13156.1; -; Genomic_DNA.
DR   EMBL; AF167460; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167462; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167463; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167464; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167465; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167466; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167468; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167470; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AY302136; AAP57628.1; -; mRNA.
DR   EMBL; AK290655; BAF83344.1; -; mRNA.
DR   EMBL; AK313818; BAG36554.1; -; mRNA.
DR   EMBL; AY228338; AAO38055.1; -; Genomic_DNA.
DR   EMBL; AC007899; AAY24317.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00407.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00408.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00409.1; -; Genomic_DNA.
DR   EMBL; BC093676; AAH93676.1; -; mRNA.
DR   EMBL; BC101475; AAI01476.1; -; mRNA.
DR   CCDS; CCDS1786.1; -. [P19525-1]
DR   CCDS; CCDS46259.1; -. [P19525-2]
DR   PIR; JC5225; JC5225.
DR   RefSeq; NP_001129123.1; NM_001135651.2. [P19525-1]
DR   RefSeq; NP_001129124.1; NM_001135652.2. [P19525-2]
DR   RefSeq; NP_002750.1; NM_002759.3. [P19525-1]
DR   RefSeq; XP_011531289.1; XM_011532987.2. [P19525-1]
DR   PDB; 1QU6; NMR; -; A=1-170.
DR   PDB; 2A19; X-ray; 2.50 A; B/C=258-550.
DR   PDB; 2A1A; X-ray; 2.80 A; B=258-550.
DR   PDB; 3UIU; X-ray; 2.90 A; A/B=254-551.
DR   PDB; 6D3K; X-ray; 2.60 A; A/B/C=229-551.
DR   PDB; 6D3L; X-ray; 3.10 A; A=229-551.
DR   PDBsum; 1QU6; -.
DR   PDBsum; 2A19; -.
DR   PDBsum; 2A1A; -.
DR   PDBsum; 3UIU; -.
DR   PDBsum; 6D3K; -.
DR   PDBsum; 6D3L; -.
DR   AlphaFoldDB; P19525; -.
DR   BMRB; P19525; -.
DR   SMR; P19525; -.
DR   BioGRID; 111596; 298.
DR   DIP; DIP-2657N; -.
DR   IntAct; P19525; 133.
DR   MINT; P19525; -.
DR   STRING; 9606.ENSP00000233057; -.
DR   BindingDB; P19525; -.
DR   ChEMBL; CHEMBL5785; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugCentral; P19525; -.
DR   GuidetoPHARMACOLOGY; 2016; -.
DR   GlyGen; P19525; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P19525; -.
DR   PhosphoSitePlus; P19525; -.
DR   SwissPalm; P19525; -.
DR   BioMuta; EIF2AK2; -.
DR   DMDM; 125527; -.
DR   EPD; P19525; -.
DR   jPOST; P19525; -.
DR   MassIVE; P19525; -.
DR   MaxQB; P19525; -.
DR   PaxDb; P19525; -.
DR   PeptideAtlas; P19525; -.
DR   PRIDE; P19525; -.
DR   ProteomicsDB; 19391; -.
DR   ProteomicsDB; 53670; -. [P19525-1]
DR   TopDownProteomics; P19525-1; -. [P19525-1]
DR   Antibodypedia; 3548; 1193 antibodies from 42 providers.
DR   DNASU; 5610; -.
DR   Ensembl; ENST00000233057.9; ENSP00000233057.4; ENSG00000055332.19. [P19525-1]
DR   Ensembl; ENST00000395127.6; ENSP00000378559.2; ENSG00000055332.19. [P19525-1]
DR   Ensembl; ENST00000405334.5; ENSP00000385014.1; ENSG00000055332.19. [P19525-2]
DR   Ensembl; ENST00000647926.1; ENSP00000497534.1; ENSG00000055332.19. [P19525-1]
DR   Ensembl; ENST00000679507.1; ENSP00000506024.1; ENSG00000055332.19. [P19525-1]
DR   Ensembl; ENST00000681463.1; ENSP00000505138.1; ENSG00000055332.19. [P19525-1]
DR   Ensembl; ENST00000681507.1; ENSP00000505772.1; ENSG00000055332.19. [P19525-1]
DR   GeneID; 5610; -.
DR   KEGG; hsa:5610; -.
DR   MANE-Select; ENST00000233057.9; ENSP00000233057.4; NM_001135651.3; NP_001129123.1.
DR   UCSC; uc010fab.3; human. [P19525-1]
DR   CTD; 5610; -.
DR   DisGeNET; 5610; -.
DR   GeneCards; EIF2AK2; -.
DR   HGNC; HGNC:9437; EIF2AK2.
DR   HPA; ENSG00000055332; Low tissue specificity.
DR   MalaCards; EIF2AK2; -.
DR   MIM; 176871; gene.
DR   MIM; 618877; phenotype.
DR   MIM; 619687; phenotype.
DR   neXtProt; NX_P19525; -.
DR   OpenTargets; ENSG00000055332; -.
DR   Orphanet; 256; Early-onset generalized limb-onset dystonia.
DR   PharmGKB; PA33779; -.
DR   VEuPathDB; HostDB:ENSG00000055332; -.
DR   eggNOG; KOG1033; Eukaryota.
DR   GeneTree; ENSGT00940000160736; -.
DR   HOGENOM; CLU_023682_1_0_1; -.
DR   InParanoid; P19525; -.
DR   OMA; LIQMEFC; -.
DR   PhylomeDB; P19525; -.
DR   TreeFam; TF317576; -.
DR   PathwayCommons; P19525; -.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-169131; Inhibition of PKR.
DR   SignaLink; P19525; -.
DR   SIGNOR; P19525; -.
DR   BioGRID-ORCS; 5610; 12 hits in 1110 CRISPR screens.
DR   ChiTaRS; EIF2AK2; human.
DR   EvolutionaryTrace; P19525; -.
DR   GeneWiki; Protein_kinase_R; -.
DR   GenomeRNAi; 5610; -.
DR   Pharos; P19525; Tchem.
DR   PRO; PR:P19525; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P19525; protein.
DR   Bgee; ENSG00000055332; Expressed in endometrium epithelium and 209 other tissues.
DR   Genevisible; P19525; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005840; C:ribosome; TAS:AgBase.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IMP:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019888; F:protein phosphatase regulator activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IEP:ARUK-UCL.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0032722; P:positive regulation of chemokine production; ISS:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB.
DR   GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISS:UniProtKB.
DR   GO; GO:1900225; P:regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0035455; P:response to interferon-alpha; IDA:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IMP:UniProtKB.
DR   GO; GO:0006412; P:translation; IEA:Ensembl.
DR   CDD; cd19903; DSRM_EIF2AK2_rpt1; 1.
DR   CDD; cd19904; DSRM_EIF2AK2_rpt2; 1.
DR   IDEAL; IID00443; -.
DR   InterPro; IPR014720; dsRBD_dom.
DR   InterPro; IPR044452; EIF2AK2_DSRM_1.
DR   InterPro; IPR044453; EIF2AK2_DSRM_2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00035; dsrm; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00358; DSRM; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50137; DS_RBD; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Antiviral defense;
KW   ATP-binding; Cytoplasm; Direct protein sequencing; Disease variant;
KW   Dystonia; Host-virus interaction; Immunity; Innate immunity;
KW   Isopeptide bond; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; RNA-binding; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..551
FT                   /note="Interferon-induced, double-stranded RNA-activated
FT                   protein kinase"
FT                   /id="PRO_0000085945"
FT   DOMAIN          9..77
FT                   /note="DRBM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          100..167
FT                   /note="DRBM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          267..538
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REPEAT          331..343
FT                   /note="1"
FT   REPEAT          345..357
FT                   /note="2"
FT   REGION          2..180
FT                   /note="(Microbial infection) Interaction with HCV NS5A"
FT                   /evidence="ECO:0000269|PubMed:17267064"
FT   REGION          202..222
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          266..551
FT                   /note="Interaction with TRAF5"
FT                   /evidence="ECO:0000269|PubMed:15121867"
FT   REGION          331..357
FT                   /note="2 X 13 AA approximate repeats"
FT   ACT_SITE        414
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         273..281
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         296
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         83
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11152499,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         88
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:11152499"
FT   MOD_RES         89
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:11152499"
FT   MOD_RES         90
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:11152499"
FT   MOD_RES         101
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16373505"
FT   MOD_RES         162
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16373505"
FT   MOD_RES         242
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:11152499"
FT   MOD_RES         255
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:11152499"
FT   MOD_RES         258
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:11152499"
FT   MOD_RES         293
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16373505"
FT   MOD_RES         446
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11337501,
FT                   ECO:0000269|PubMed:16179258"
FT   MOD_RES         451
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11337501,
FT                   ECO:0000269|PubMed:20685959"
FT   MOD_RES         456
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         542
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        69
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ISG15)"
FT                   /evidence="ECO:0000269|PubMed:23229543"
FT   CROSSLNK        159
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ISG15)"
FT                   /evidence="ECO:0000269|PubMed:23229543"
FT   VAR_SEQ         263..303
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_046177"
FT   VARIANT         11
FT                   /note="M -> L (in LEUDEN; unknown pathological
FT                   significance; reduced phosphorylation of eukaryotic
FT                   translation initiation factor 2-alpha in patient cells)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084260"
FT   VARIANT         32
FT                   /note="N -> S (in LEUDEN; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084261"
FT   VARIANT         32
FT                   /note="N -> T (in DYT33; unknown pathological significance;
FT                   gain-of-function variant resulting in increased levels of
FT                   phosphorylated EIF2AK2 and EIF2A in patient cells compared
FT                   to controls)"
FT                   /evidence="ECO:0000269|PubMed:33236446"
FT                   /id="VAR_086715"
FT   VARIANT         97
FT                   /note="S -> F (in LEUDEN; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084262"
FT   VARIANT         109
FT                   /note="A -> S (in LEUDEN; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084263"
FT   VARIANT         109
FT                   /note="A -> V (in LEUDEN; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084264"
FT   VARIANT         114
FT                   /note="L -> Q (found in a patient with dysmorphic facies,
FT                   syndactyly, congenital microcephaly and global
FT                   developmental delay; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084265"
FT   VARIANT         130
FT                   /note="G -> R (in DYT33; gain-of-function variant resulting
FT                   in increased levels of phosphorylated EIF2AK2 and EIF2A in
FT                   patient cells compared to controls)"
FT                   /evidence="ECO:0000269|PubMed:33236446,
FT                   ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068"
FT                   /id="VAR_086716"
FT   VARIANT         133
FT                   /note="Y -> F (in LEUDEN; unknown pathological
FT                   significance; reduced phosphorylation of eukaryotic
FT                   translation initiation factor 2-alpha in patient cells)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084266"
FT   VARIANT         138
FT                   /note="G -> A (in DYT33; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:33236446"
FT                   /id="VAR_086717"
FT   VARIANT         325
FT                   /note="G -> S (in LEUDEN; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084267"
FT   VARIANT         428
FT                   /note="V -> E (in dbSNP:rs56219559)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040474"
FT   VARIANT         439
FT                   /note="L -> V (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040475"
FT   VARIANT         461
FT                   /note="S -> C (in LEUDEN; unknown pathological
FT                   significance; reduced phosphorylation of eukaryotic
FT                   translation initiation factor 2-alpha in patient cells)"
FT                   /evidence="ECO:0000269|PubMed:32197074"
FT                   /id="VAR_084268"
FT   VARIANT         506
FT                   /note="I -> V (in dbSNP:rs34821155)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040476"
FT   MUTAGEN         59..60
FT                   /note="SK->AA: In FL-PKR-2AI; moderate loss of activity but
FT                   no effect on dsRNA binding."
FT                   /evidence="ECO:0000269|PubMed:11337501"
FT   MUTAGEN         60
FT                   /note="K->A: Impairs dsRNA binding but not dimerization or
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11337501"
FT   MUTAGEN         67
FT                   /note="A->E: Significant loss of activity; loss of dsRNA
FT                   binding and dimerization."
FT                   /evidence="ECO:0000269|PubMed:11337501"
FT   MUTAGEN         83
FT                   /note="S->A: No effect on enzymatic activity; when
FT                   associated with A-88; A-89 and A-90."
FT                   /evidence="ECO:0000269|PubMed:11152499"
FT   MUTAGEN         88
FT                   /note="T->A: No effect on enzymatic activity; when
FT                   associated with A-83; A-89 and A-90."
FT                   /evidence="ECO:0000269|PubMed:11152499"
FT   MUTAGEN         89
FT                   /note="T->A: No effect on enzymatic activity; when
FT                   associated with A-83; A-88 and A-90."
FT                   /evidence="ECO:0000269|PubMed:11152499"
FT   MUTAGEN         90
FT                   /note="T->A: No effect on enzymatic activity; when
FT                   associated with A-83; A-88 and A-89."
FT                   /evidence="ECO:0000269|PubMed:11152499"
FT   MUTAGEN         149..150
FT                   /note="TK->AA: In FL-PKR-2AII; no effect on activity."
FT                   /evidence="ECO:0000269|PubMed:11337501"
FT   MUTAGEN         242
FT                   /note="S->A: Moderate loss of activity; when associated
FT                   with A-255 and A-258."
FT                   /evidence="ECO:0000269|PubMed:11152499"
FT   MUTAGEN         244..296
FT                   /note="Missing: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11337501"
FT   MUTAGEN         255
FT                   /note="T->A: Moderate loss of activity; when associated
FT                   with A-242 and A-255."
FT                   /evidence="ECO:0000269|PubMed:11152499"
FT   MUTAGEN         258
FT                   /note="T->A: Moderate loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11152499"
FT   MUTAGEN         296
FT                   /note="K->R: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11152499"
FT   MUTAGEN         446
FT                   /note="T->A: Significant loss of activity and impairs
FT                   autophosphorylation of T-451."
FT                   /evidence="ECO:0000269|PubMed:11337501"
FT   MUTAGEN         451
FT                   /note="T->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11337501"
FT   CONFLICT        102
FT                   /note="I -> M (in Ref. 7; AAP57628)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        224
FT                   /note="S -> R (in Ref. 7; AAP57628)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        512
FT                   /note="K -> E (in Ref. 6; AAF13156)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..7
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   HELIX           10..21
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   STRAND          26..32
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   TURN            35..37
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   STRAND          41..50
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   STRAND          54..56
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   HELIX           61..76
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   HELIX           102..111
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   STRAND          115..123
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   STRAND          125..138
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   STRAND          144..149
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   HELIX           150..167
FT                   /evidence="ECO:0007829|PDB:1QU6"
FT   HELIX           261..266
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          267..274
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          276..278
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          281..286
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   TURN            287..289
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          292..299
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           303..305
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           306..314
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          323..332
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          358..366
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           374..380
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           381..383
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           388..407
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          410..412
FT                   /evidence="ECO:0007829|PDB:2A1A"
FT   HELIX           417..419
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          420..424
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          427..430
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           433..435
FT                   /evidence="ECO:0007829|PDB:6D3L"
FT   STRAND          437..440
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           457..461
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           468..482
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           488..499
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   STRAND          505..507
FT                   /evidence="ECO:0007829|PDB:3UIU"
FT   HELIX           509..518
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           523..525
FT                   /evidence="ECO:0007829|PDB:2A19"
FT   HELIX           529..539
FT                   /evidence="ECO:0007829|PDB:2A19"
SQ   SEQUENCE   551 AA;  62094 MW;  815AD83ACAB45DA3 CRC64;
     MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK
     KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ
     CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG
     SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK
     RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY
     NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK
     CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI
     FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE
     LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK
     KSPEKNERHT C
//
